Loading
What changed between revision 1 and revision 3, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/sens-research-foundation.md — the filesystem corpus, unchanged. Not an edit.
11.6 kB
Revision 1
Revision 3
lines 6–14 → 6–135 unchanged lines not shown
horizon: "present"horizon: "present"categories: ["organizations", "longevity"]categories: ["organizations", "longevity"]tags: ["aging", "damage repair", "nonprofit", "rejuvenation", "research funding", "sens"]tags: ["aging", "damage repair", "nonprofit", "rejuvenation", "research funding", "sens"]summary: "A California nonprofit founded in 2009 to fund rejuvenation research organized around seven categories of accumulated cellular damage, renamed Lifespan Research Institute in 2024."summary: "A California nonprofit founded in 2009 to fund rejuvenation research organized around seven categories of accumulated cellular damage, merged into the Lifespan Research Institute in 2024."updated: "2026-07-27"updated: "2026-10-29"issues: ["The Thiel and Buterin donations are named without a source", "The 2021 investigation's reported conclusion needs a citation"]------ ```infobox```infoboxlines 20–38 → 19–375 unchanged lines not shown
{ "label": "Parent organization", "value": "Methuselah Foundation", "link": "/wiki/methuselah-foundation" }, { "label": "Parent organization", "value": "Methuselah Foundation", "link": "/wiki/methuselah-foundation" }, { "label": "Headquarters", "value": "Mountain View, California" }, { "label": "Headquarters", "value": "Mountain View, California" }, { "label": "Framework", "value": "Seven damage categories" }, { "label": "Framework", "value": "Seven damage categories" }, { "label": "Renamed", "value": "2024, as Lifespan Research Institute" }, { "label": "Merged", "value": "2024, into Lifespan Research Institute" }, { "label": "Funding", "value": "Philanthropic" } { "label": "Funding", "value": "Philanthropic" } ] ]}}`````` **SENS Research Foundation** is a California nonprofit established in 2009 to fund research on Strategies for Engineered Negligible Senescence, a framework that treats aging as the accumulation of seven classes of cellular and molecular damage, each of which is to be repaired directly rather than prevented. Spun out of the [[methuselah-foundation]] by [[aubrey-de-grey]] and colleagues, it was for a decade the main institutional home of the damage-repair approach to aging. It removed de Grey in 2021 after allegations of misconduct, and rebranded as the Lifespan Research Institute in 2024.**SENS Research Foundation** is a California nonprofit established in 2009 to fund research on Strategies for Engineered Negligible Senescence, a framework that treats aging as the accumulation of seven classes of cellular and molecular damage, each to be repaired directly rather than prevented. Spun out of the [[methuselah-foundation]] by [[aubrey-de-grey]] and colleagues, it was for a decade the main institutional home of the damage-repair approach to aging. It removed de Grey in 2021 after allegations of misconduct, and in 2024 merged with the advocacy organization Lifespan.io to form the Lifespan Research Institute. ## Overview## Overview The SENS framework's distinguishing claim is engineering rather than biological. Its proponents argue that understanding the metabolic processes that generate damage is not necessary in order to remove the damage, in the same way that a mechanic need not understand combustion chemistry to replace a corroded part. This is a deliberate contrast with the mainstream [[geroscience-hypothesis]], which seeks to slow damage accumulation by modulating pathways such as mTOR and nutrient sensing with drugs like [[rapamycin]], and with the descriptive [[hallmarks-of-aging]] framework, which SENS advocates regard as a taxonomy that stops short of telling anyone what to build.The SENS framework makes an engineering claim rather than a biological one. Its proponents argue that removing damage does not require understanding the metabolic processes that generate it, in the same way that a mechanic need not understand combustion chemistry to replace a corroded part. The framework deliberately contrasts with the mainstream [[geroscience-hypothesis]], which seeks to slow damage accumulation by modulating pathways such as mTOR and nutrient sensing with drugs like [[rapamycin]]. It also contrasts with the descriptive [[hallmarks-of-aging]] framework, which SENS advocates regard as a taxonomy that stops short of telling anyone what to build. The framework enumerates seven damage categories, and asserts that the list is complete in the sense that no new class of damage has been discovered since the 1980s:The framework enumerates seven damage categories and asserts that the list is complete, in the sense that no new class of damage has been discovered since the 1980s: - cell loss and tissue atrophy- cell loss and tissue atrophy- death-resistant cells, principally [[cellular-senescence|senescent cells]]- death-resistant cells, principally [[cellular-senescence|senescent cells]]lines 43–55 → 42–544 unchanged lines not shown
- extracellular protein crosslinks, principally glucosepane in collagen- extracellular protein crosslinks, principally glucosepane in collagen > [!debate] Repair or slow down> [!debate] Repair or slow down> The damage-repair position holds that intervention should target the accumulated products of aging, which are enumerable, rather than the metabolism that produces them, which is not fully understood. Most biogerontologists regard the seven-category list as an assertion rather than a finding, and note that the boundary between damage and normal biological variation is not sharp. The disagreement is about research strategy, not about whether damage accumulates.> The damage-repair position holds that intervention should target the accumulated products of aging, which can be enumerated, rather than the metabolism that produces them, which is not fully understood. Most biogerontologists regard the seven-category list as an assertion rather than a finding, and note that the boundary between damage and normal biological variation is not sharp. Both sides agree that damage accumulates; the disagreement is over research strategy. ## History## History De Grey developed the framework in the early 2000s, initially at Cambridge, and set out its full form in 2007 in *Ending Aging*, written with Michael Rae.[^degrey2007] The Methuselah Foundation, which de Grey had co-founded with David Gobel in the early 2000s, funded early SENS work; in 2009 SENS Foundation was incorporated separately with de Grey, Michael Kope, Jeff Hall, Sarah Marr and Kevin Perrott among its founders.De Grey developed the framework in the early 2000s, initially at Cambridge, and set out its full form in 2007 in *Ending Aging*, written with Michael Rae.[^degrey2007] The Methuselah Foundation, which de Grey had co-founded with David Gobel in the early 2000s, funded early SENS work. In 2009 SENS Foundation was incorporated separately, with de Grey, Michael Kope, Jeff Hall, Sarah Marr and Kevin Perrott among its founders. The organization ran an intramural laboratory in Mountain View, funded extramural projects at universities, and operated an education programme that placed undergraduates in aging laboratories. Its early funding came heavily from individual donors in the technology sector, including a substantial early gift from Peter Thiel and, later, cryptocurrency donations from Vitalik Buterin.The organization ran an intramural laboratory in Mountain View, funded extramural projects at universities, and operated an education programme that placed undergraduates in aging laboratories. Much of its early funding came from individual donors in the technology sector. Before the spin-out, in 2006, Peter Thiel had pledged $3.5 million to the Methuselah Foundation specifically for SENS research, made up of $500,000 in direct funding plus up to $3 million in matching funds.[^fightaging2006] Vitalik Buterin donated $2.4 million in ether to the foundation in 2018.[^buterin2018] ```timeline```timeline[[lines 58–64 → 57–632 unchanged lines not shown
{ "year": "2009", "title": "SENS Foundation founded", "text": "The programme is spun out of the Methuselah Foundation as an independent nonprofit with its own laboratory in Mountain View." }, { "year": "2009", "title": "SENS Foundation founded", "text": "The programme is spun out of the Methuselah Foundation as an independent nonprofit with its own laboratory in Mountain View." }, { "year": "2010s", "title": "Spin-outs", "text": "Funded projects yield companies including Cyclarity Therapeutics, working on cyclodextrins for arterial cholesterol, and Revel Pharmaceuticals, working on crosslink-breaking enzymes." }, { "year": "2010s", "title": "Spin-outs", "text": "Funded projects yield companies including Cyclarity Therapeutics, working on cyclodextrins for arterial cholesterol, and Revel Pharmaceuticals, working on crosslink-breaking enzymes." }, { "year": "2021", "title": "Governance crisis", "text": "Allegations of misconduct lead to de Grey being placed on leave and then removed; he denies wrongdoing and later founds the LEV Foundation." }, { "year": "2021", "title": "Governance crisis", "text": "Allegations of misconduct lead to de Grey being placed on leave and then removed; he denies wrongdoing and later founds the LEV Foundation." }, { "year": "2024", "title": "Renamed", "text": "The organization becomes the Lifespan Research Institute, retaining the damage-repair research agenda under new leadership." } { "year": "2024", "title": "Merged", "text": "SENS Research Foundation and the advocacy organization Lifespan.io combine to form the Lifespan Research Institute, which keeps a research and education centre in Mountain View." }]]`````` lines 66–96 → 65–951 unchanged line not shown
The foundation's approach was to fund the categories that no one else was working on. Cell loss is addressed by mainstream regenerative medicine and [[induced-pluripotent-stem-cells|stem cell]] research; cancer attracts enormous investment; senescent cells acquired a large commercial following after 2015 with the rise of [[senolytics]]. The organization concentrated its own money on the neglected remainder.The foundation's approach was to fund the categories that no one else was working on. Cell loss is addressed by mainstream regenerative medicine and [[induced-pluripotent-stem-cells|stem cell]] research; cancer attracts enormous investment; senescent cells acquired a large commercial following after 2015 with the rise of [[senolytics]]. The organization concentrated its own money on the neglected remainder. Two lines produced spin-out companies. Work on lysosomal aggregates in atherosclerosis — 7-ketocholesterol, which macrophages cannot degrade and which contributes to foam-cell formation — led to Cyclarity Therapeutics, founded by Matthew O'Connor, which developed an engineered cyclodextrin intended to extract the molecule from plaque and began first-in-human testing in Australia in the mid-2020s. Work on glucosepane, the dominant crosslink in aged human collagen, led to Revel Pharmaceuticals, founded with the Yale chemist David Spiegel, which pursued enzymes capable of cleaving it.Two lines produced spin-out companies. One studied lysosomal aggregates in atherosclerosis, specifically 7-ketocholesterol, which macrophages cannot degrade and which contributes to foam-cell formation. It led to Cyclarity Therapeutics, founded by Matthew O'Connor, which developed an engineered cyclodextrin intended to extract the molecule from plaque and began first-in-human testing in Australia in the mid-2020s. The other studied glucosepane, the dominant crosslink in aged human collagen, and led to Revel Pharmaceuticals, founded with the Yale chemist David Spiegel, which pursued enzymes capable of cleaving it. A third line, mitochondrial [[gene-therapy-for-aging|gene therapy]] by allotopic expression — inserting backup copies of the thirteen mitochondrially encoded genes into the nucleus so that a cell with damaged mitochondrial DNA can still make the proteins — was pursued in the foundation's own laboratory and produced published results for a subset of the genes. It has not reached human testing, and the approach is distinct from the [[mitochondrial-replacement-therapy|germline replacement]] techniques used to prevent inherited mitochondrial disease.A third line, pursued in the foundation's own laboratory, was mitochondrial [[gene-therapy-for-aging|gene therapy]] by allotopic expression: inserting backup copies of the thirteen mitochondrially encoded genes into the nucleus, so that a cell with damaged mitochondrial DNA can still make the proteins. It produced published results for a subset of the genes but has not reached human testing. The approach is distinct from the [[mitochondrial-replacement-therapy|germline replacement]] techniques used to prevent inherited mitochondrial disease. ## The 2005 challenge## The 2005 challenge In 2005 *MIT Technology Review* offered a prize to any molecular biologist who could demonstrate that SENS was "so wrong that it is unworthy of learned debate". Submissions were judged by a panel including Rodney Brooks, Anita Goel, Nathan Myhrvold, Vikram Sheel Kumar and J. Craig Venter. No prize was awarded. The judges' conclusion, which both sides have quoted selectively ever since, was that the critics had not proven SENS false but that de Grey had not proven it plausible either, and that it belonged in the category of ideas that are unsupported rather than refuted.[^pontin2006] Two decades later that verdict has aged well: several SENS categories have become mainstream research areas, and none has produced a demonstrated human rejuvenation therapy.In 2005 *MIT Technology Review* offered a prize to any molecular biologist who could demonstrate that SENS was "so wrong that it is unworthy of learned debate". A panel including Rodney Brooks, Anita Goel, Nathan Myhrvold, Vikram Sheel Kumar and J. Craig Venter judged the submissions, and no prize was awarded. The judges concluded that the critics had not proven SENS false but that de Grey had not proven it plausible either, and that it belonged among ideas that are unsupported rather than refuted; both sides have quoted that conclusion selectively ever since.[^pontin2006] Two decades later the verdict still fits. Several SENS categories have become mainstream research areas, and none has produced a demonstrated human rejuvenation therapy. ## Funding## Funding The organization has always been philanthropically funded, with annual budgets in the single-digit millions of dollars — small relative to [[calico]] or [[altos-labs]] by three orders of magnitude, and small relative to national aging-research budgets. Its donor base was concentrated, which made it vulnerable to the loss of individual supporters and shaped the governance problems that followed.The organization has always been philanthropically funded, with annual budgets in the single-digit millions of dollars. That is three orders of magnitude smaller than [[calico]] or [[altos-labs]], and small relative to national aging-research budgets. Its donor base was concentrated, which left it vulnerable to the loss of individual supporters and shaped the governance problems that followed. Cryptocurrency donations were significant during the 2017 and 2021 market peaks and volatile in the way that implies. Nominal values reported at the time of donation frequently exceeded what was realized.Cryptocurrency donations were significant during the 2017 and 2021 market peaks, and as volatile as that implies. Nominal values reported at the time of donation frequently exceeded what was realized. ## The 2021 crisis and rebranding## The 2021 crisis and the merger In August 2021 two women made public allegations concerning de Grey's conduct. The foundation placed him on administrative leave and commissioned an independent investigation, then terminated his employment. The investigation's reported conclusion was that it had not substantiated a finding of sexual harassment but that de Grey had improperly interfered with the investigation itself. De Grey denied wrongdoing throughout and subsequently reached a settlement with the organization; he founded the Longevity Escape Velocity Foundation in 2022, named for the [[longevity-escape-velocity]] threshold he had popularized, to run large mouse studies combining several interventions at once.In August 2021 two women made public allegations concerning de Grey's conduct. The foundation placed him on administrative leave and commissioned an independent investigation by an outside law firm. On 21 August 2021 it removed him as chief science officer, stating that it could not permit him to "undercut or disrupt the investigator's work"; the immediate ground for the dismissal was interference with the inquiry, not the inquiry's findings.[^molteni2021a] The investigation concluded that November. Its reported findings were incidents of unprofessional, boundary-crossing behaviour, together with a determination that the investigators had not found evidence of non-consensual sexual contact or communications, and the board said the conclusions did not change its decision.[^molteni2021b] De Grey denied wrongdoing throughout. He later founded the Longevity Escape Velocity Foundation, named for the [[longevity-escape-velocity]] threshold he had popularized, to run large mouse studies combining several interventions at once. The episode cost the organization donors, staff and its most recognizable public figure at once. Under new leadership it narrowed its programme, and in 2024 renamed itself the Lifespan Research Institute, a change that separated the organization's identity from both the SENS acronym and its founder.The episode cost the organization donors, staff and its most recognizable public figure at the same time. In October 2024 it merged with Lifespan.io (the Lifespan Extension Advocacy Foundation, a New York nonprofit founded in 2014) to form the **Lifespan Research Institute**. The combined organization, led by chief executive Lisa Fabiny-Kiser, pairs the Mountain View research and education centre with Lifespan.io's outreach programmes.[^lifespanio2024][^longevitytech2024] The merger detached the organization's identity from both the SENS acronym and its founder. The new institute describes its mission as developing and promoting access to regenerative medicine for the diseases of aging, a formulation markedly closer to mainstream regenerative medicine than to the original damage-repair rhetoric. ## Reception and legacy## Reception and legacy Mainstream biogerontology has never accepted the SENS framework as a theory, and a 2005 rebuttal in *EMBO Reports* signed by a group of prominent aging researchers argued that it presents speculative proposals as an engineering roadmap and that none of the seven interventions had a demonstrated route to the clinic.[^warner2005] That criticism was substantially correct at the time and remains largely correct.Mainstream biogerontology has never accepted the SENS framework as a theory. A 2005 rebuttal in *EMBO Reports*, signed by a group of prominent aging researchers, argued that it presents speculative proposals as an engineering roadmap and that none of the seven interventions had a demonstrated route to the clinic.[^warner2005] That criticism was substantially correct at the time and remains largely correct. The foundation's actual influence runs through people and topics rather than through the framework. It funded senescent-cell work before senolytics were fashionable, kept crosslink chemistry and lysosomal aggregate research alive when no one else would pay for them, and trained a cohort of researchers now distributed across the field and the [[buck-institute]] and comparable centres. It also normalized the idea that aging is a legitimate target for intervention rather than an inevitability, which made the funding environment that produced Altos, [[retro-biosciences]] and [[xprize-healthspan]] easier to create.The foundation's actual influence runs through people and topics rather than through the framework. It funded senescent-cell work before senolytics were fashionable, kept crosslink chemistry and lysosomal aggregate research alive when no one else would pay for them, and trained a cohort of researchers now spread across the field, including at the [[buck-institute]] and comparable centres. It also normalized the idea that aging is a legitimate target for intervention rather than an inevitability, which made it easier to create the funding environment that produced Altos, [[retro-biosciences]] and [[xprize-healthspan]]. Whether the seven-category framework is the right decomposition remains unsettled. It is at least falsifiable in principle: if a repair therapy for one category produced a measurable rejuvenation in a mammal without touching the others, the framework's modular premise would gain support it currently lacks.Whether the seven-category framework is the right decomposition remains unsettled. It is at least falsifiable in principle: if a repair therapy for one category produced a measurable rejuvenation in a mammal without touching the others, the framework's modular premise would gain support it currently lacks. lines 110–113 → 109–11813 unchanged lines not shown
[^degrey2007]: `book` de Grey, A. and Rae, M. *Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime*. St. Martin's Press, 2007.[^degrey2007]: `book` de Grey, A. and Rae, M. *Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime*. St. Martin's Press, 2007.[^pontin2006]: `news` Pontin, J. "Is Defeating Aging Only A Dream?" *MIT Technology Review*, 2006. {The magazine both ran the challenge and published this account of its outcome, so it is a party to the episode as well as a source on it.}[^pontin2006]: `news` Pontin, J. "Is Defeating Aging Only A Dream?" *MIT Technology Review*, 2006. {The magazine both ran the challenge and published this account of its outcome, so it is a party to the episode as well as a source on it.}[^warner2005]: `paper` Warner, H., Anderson, J., Austad, S. et al. "Science fact and the SENS agenda." *EMBO Reports*, 2005. {A signed critique rather than a research report; it argues from the state of the evidence in 2005 and presents no new experiment.}[^warner2005]: `paper` Warner, H., Anderson, J., Austad, S. et al. "Science fact and the SENS agenda." *EMBO Reports*, 2005. {A signed critique rather than a research report; it argues from the state of the evidence in 2005 and presents no new experiment.}[^fightaging2006]: `news` "Peter Thiel Gives Us All a $6 Million Challenge." *Fight Aging!*, September 2006. {An advocacy blog reproducing the pledge's press-release terms ($500,000 over three years plus up to $3 million in matching funds through 2009); it records the commitment, not what was ultimately disbursed.}[^buterin2018]: `news` "Vitalik Buterin Donates $2.4 Million in Ether to Anti-Aging Research." *Cointelegraph*, February 2018. {Reports the donation's nominal dollar value at the time of transfer; ether's subsequent price movements are not reflected.}[^molteni2021a]: `news` Molteni, M. "SENS Research Foundation removes Aubrey de Grey over concerns he was interfering in sexual harassment investigation." *STAT*, 22 August 2021.[^molteni2021b]: `news` Molteni, M. "Anti-aging research foundation stands by ouster of Aubrey de Grey after investigation concludes." *STAT*, 9 November 2021. {Reports the concluded investigation's findings (unprofessional, boundary-crossing behaviour, and no evidence found of non-consensual sexual contact) and the board's decision to stand by the dismissal.}[^lifespanio2024]: `statement` Lifespan.io / Lifespan Research Institute. "Lifespan.io and SENS Research Foundation Unite." lifespan.io, October 2024. {The merged organization's own announcement; it is a party to the merger it describes and records its stated leadership and programmes.}[^longevitytech2024]: `news` "Lifespan Research Institute: SENS and Lifespan.io merge." *Longevity.Technology*, 9 October 2024. removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
92 lines are the same in both revisions, and 30 of them are not shown. Neither revision here is necessarily the current article — read SENS Research Foundation for the text this wiki stands behind today.